Researchers in Chicago have developed a method by which to deliver a breast cancer-preventing drug through the skin to avoid some of the nasty side effects associated with oral ingestion of the drug.
Here at FierceDrugDelivery, we write often about innovations in nanotechnology as it becomes more and more important in the delivery field. These advances are mostly in the very early stages, but they're still promising as the delivery field moves even further into the nanoscale. Last year's report highlighted some companies that have since made an even bigger impact in biotech as a whole, including the newly public Bind Therapeutics and hot RNAi specialist Alnylam. You'll see familiar names in both the industry and the academic realm in this year's report, among others that have offered important developments to the arena. Check out the report >>
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
POPULAR COMMENT THREADS
Researchers at the University of Pennsylvania said they have uncovered a delivery method to treat acute pulmonary inflammation, a condition that afflicts patients suffering from multiple blood transfusions, sepsis, lung surgery and acute lung trauma and has a mortality rate as high as 40%.
A record-breaking material discovered last year by Swedish researchers has passed another milestone for drug delivery, showing it can hold poorly soluble drugs and, down the road, deliver them with a fast dissolution rate.
Gold nanoparticles are once again in the drug delivery spotlight as MIT scientists have discovered a mechanism by which the particles enter cells and could thus act as better drug carriers.
Alnylam announced July 22 that its intellectual property estate has been strengthened due to the U.S. Patent Office's issuance of a Notice of Allowance for claims in one of its patent applications that covers "chemically modified RNA therapeutics conjugated with an N-acetylgalactosamine (GalNAc) ligand independent of length, sequence, or disease target," according to a statement.
A year after the FDA rejected Titan Pharmaceutical's Probuphine subdermal implant for the treatment of opioid dependence, the company is knocking on the approval door once again. It announced July 21 that the first patients have enrolled in its Phase III trial designed to address the FDA's questions.
Galena Biopharma believes that its experienced oncology sales team will enable it to effectively market Zuplenz, the only oral soluble film for preventing vomiting following chemotherapy and radiotherapy, which it will soon offer thanks to a licensing agreement struck with MonoSol Rx, the developer of the product's delivery technology.
From Our Sister Sites
In response to back-to-back incidents involving government laboratories, a top official at the U.S. Centers for Disease Control and Prevention has resigned, and the agency has assembled a safety board to address concerns that have arisen after workers were potentially exposed to anthrax and H5N1 flu.
Merck is going through a complete makeover, buying and selling units at a rapid pace. And some of its employees are getting caught in its "out with the old and in with the new" philosophy. Now 600 sales reps have been told their services are no longer needed